News
-
-
-
-
-
-
PRESS RELEASE
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz Group AG confirms European Commission approval for biosimilars Bysumlog(R) (insulin lispro) and Dazparda(R) (insulin aspart), strengthening position in diabetes -
-
-
-